Acorda Therapeutics price target raised to $30 from $28 at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju raised his price target for Acorda Therapeutics to $30 following the company’s Q3 results. Acorda’s original guidance assumed significantly faster attrition in the Ampyra franchise from generics than has turned out to be the case, Selvaraju tells investors in a research note. There remains a “reasonable likelihood” of lower than expected erosion of the Ampyra revenue base going forward, “providing fuel for Acorda to continue to outperform,” says the analyst. He keeps a Buy rating on Acorda Therapeutics.
https://thefly.com/landingPageNews.php?id=2817247

Repligen price target raised to $60 from $49 at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju raised his price target for Repligen to $60 but reiterates a Neutral rating on the name. Solid execution produced a “modest beat” in Q3, but the stock reaction may have been overdone, Selvaraju tells investors in a research note. He believes the stock “still looks expensive.”
https://thefly.com/landingPageNews.php?id=2817255

BioTime receives second installment payment of $10.8M from Juvenescence

BioTime announced that it has received the second installment payment of $10.8M pursuant to the previously-announced sale of shares of AgeX Therapeutics to Juvenescence. Following the completion of the planned distribution of AgeX shares to BioTime shareholders, BioTime will retain an approximately 4.9% ownership in AgeX. Notably, the milestones and royalties in the current licensing agreement between BioTime and AgeX were not changed as part of the Juvenescence transaction.
https://thefly.com/landingPageNews.php?id=2817297

Immunomedics initiated

Immunomedics started with an Overweight rating, $38 target at Morgan Stanley. As previously reported, Morgan Stanley analyst Matthew Harrison initiated Immunomedics with an Overweight rating, stating that he expects IMMU-132 to be approved by its PDUFA date in January 2019 and expects rapid adoption of the drug after that. The drug is initially focused in late-line triple negative breast cancer, but he believes expansion to earlier lines of therapy can drive over $1B in peak sales, Harrison tells investors. He set a $38 price target on Immunomedics shares.
https://thefly.com/landingPageNews.php?id=2817301

NinePoint Medical announces FDA clearance of NvisionVLE Imaging System

NinePoint Medical announced that it has received FDA clearance to market its Intelligent Real-time Image Segmentation software upgrade for its flagship product, the NvisionVLE Imaging System. IRIS, an artificial intelligence-based platform for image feature segmentation, is the first tool of its kind approved for use in imaging of esophageal tissue. The clearance of IRIS marks the first product addition to the NvisionVLE Imaging System family since NinePoint Medical began a strategic collaboration with its worldwide distributor, Merit Medical Systems.
https://thefly.com/landingPageNews.php?id=2817331

Abiomed data could help double addressable market, says Jefferies

Abiomed will report data from its ST segment elevation myocardial infarction Door to Unloading study on November 11, Jefferies analyst Raj Denhoy tells investors in a research note. The analyst says that while only designed as a feasibility study with 50 patients, the rationale for the study and results from previous studies suggest it could show more than just equivalence. Any positive result would add support to the idea that Abiomed is well on its way to opening up a market of 200,000-300,000 patients per year worth $4B-$6B in the U.S. alone, says Denhoy. This would essentially double the addressable market for Impella, the analyst adds. He keeps a Buy rating on Abiomed with a $400 price target.
https://thefly.com/landingPageNews.php?id=2817341

AcelRx to host conference call

Conference call to discuss the FDA approval of DSUVIA will be held on November 5 at 8:30 am.

Webcast: http://ir.acelrx.com/upcoming-events
https://thefly.com/landingPageNews.php?id=2816901